| Literature DB >> 27095942 |
Nilüfer Avcı1, Mustafa Hartavi2, Turgut Kaçan3, Murat Bayındır2, Mustafa Avcı2, Cüneyt Özakın4, Aynur Engin5, Adem Deliqönüll6, Turkkan Evrensel6, Halis Akalın5.
Abstract
AIM OF THE STUDY: The spectrum of pulmonary infections in patients with lung cancer is wide, and tools for target-oriented infection control measures are necessary. In this retrospective study we report the microbiological spectrum of pneumonia (based on the results of sputum culture) in a case series of Turkish patients with lung malignancies.Entities:
Keywords: Aspergillus fumigatus; febrile neutropaenia; lung cancer; pneumonia
Year: 2016 PMID: 27095942 PMCID: PMC4829750 DOI: 10.5114/wo.2016.58502
Source DB: PubMed Journal: Contemp Oncol (Pozn) ISSN: 1428-2526
General characteristics of patients with lung cancer and pneumonia
| Variable | Study patients ( | |
|---|---|---|
| Male sex, | 111 (93.3) | |
| Age (years) | 59.8 ±9.6 | |
| Diabetes mellitus, | 13 (10.9) | |
| COPD, | 11 (9.2) | |
| Histology, | ||
| Squamous cell carcinoma | 53 (44.5) | |
| Adenocarcinoma | 51 (42.8) | |
| Small cell lung cancer | 15 (12.7) | |
| Tumour stage, | ||
| 1 | 0 (0) | |
| 2 | 13 (10.9) | |
| 3 | 28 (23.5) | |
| 4 | 71 (59.7) | |
| Unknown | 7 (5.9) | |
| Tumour localisation, | ||
| Central | 44 (36.9) | |
| Peripheral | 75 (63.1) | |
| Surgical treatment, | 26 (21.8) | |
| Pleural effusion, | 25 (21.0) | |
| Haemoglobin, g/l | 10.2 (6.0–15.0) | |
| C-reactive protein, mg/dl | 12.1 (0.34–324.6) | |
| Creatinine, mg/dl | 0.8 (0.4–1.9) | |
| White blood count, mm3 | 10,400 (500–216,000) | |
COPD – chronic obstructive pulmonary disease. Data are presented as means and SD, counts, or medians and interquartile ranges, as appropriate.
Multivariate analysis of having a positive Aspergillus fumigatus sputum culture in the study patients (n = 119)
| Variable | Odds ratio (95% CI) | |
|---|---|---|
| Male sex | 1.01 (0.96–1.89) | NS |
| Age | 1.21 (0.73–2.13) | NS |
| Diabetes mellitus | 1.34 (0.91–1.67) | NS |
| COPD | 1.98 (0.97–2.45) | NS |
| Histology | 0.86 (0.59–1.06) | NS |
| Tumour stage | 1.12 (0.89–1.44) | NS |
| Tumour localisation | 0.78 (0.61–1.82) | NS |
| Surgical treatment | 1.04 (0.97–1.12) | NS |
| Pleural effusion | 0.98 (0.86–1.86) | NS |
| Hospital-acquired pneumonia | 1.33 (0.91–2.30) | NS |
| Chemotherapy dose modifications | 1.34 (0.90–1.78) | NS |
| Respiratory failure | 1.11 (0.87–1.95) | NS |
| Febrile neutropaenia | 1.32 (1.17–3.68) | < 0.05 |
| Development of pneumonia within the first 10 days | 1.78 (1.37–4.12) | < 0.01 |
CI – confidence interval; NS – not significant